|
Delayed
London S.E.
04:59:33 23/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.0950 GBX | -5.00% |
|
-13.64% | -62.75% |
| 22/10 | WINNERS & LOSERS: Camellia slumps on macadamia woe; Record climbs | AN |
| 20/10 | WINNERS & LOSERS: Ixico beats expectations; Shearwater wins deal | AN |
| Market Cap | 37.84L 50.58L 45.15L 41.65L 70.99L 48Cr 72.08L 5.02Cr 1.98Cr 25Cr 1.9Cr 1.86Cr 80Cr | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 36.87L 49.28L 43.98L 40.58L 69.16L 47Cr 70.22L 4.89Cr 1.93Cr 24Cr 1.85Cr 1.81Cr 77Cr | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Deutsche Boerse AG
| 1RT | Delayed | |
|
Börse Stuttgart
| 1RT | Delayed |
| 23/25/23 | Nuformix : Prospectus | PU |
| 05/23/05 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/22/20 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/22/20 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/20/18 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 day | -5.00% | ||
| 1 week | -13.64% | ||
| Current month | -34.48% | ||
| 1 month | -29.63% | ||
| 3 months | -44.12% | ||
| 6 months | -47.22% | ||
| Current year | -62.75% |
| 1 week | 0.09 |  | 0.13 |
| 1 month | 0.09 | | 0.16 |
| Current year | 0.09 | | 0.4 |
| 1 year | 0.09 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 29/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 02/12/2020 | |
Timothy Metcalfe
CHM | Chairman | 54 | 01/09/2026 |
Daniel Gooding
BRD | Director/Board Member | 53 | 01/07/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 05/11/24 | Free | Director | 2,20,00,000 | 2.6852% | ||
| 05/11/24 | Free | Chairman | 2,20,00,000 | 2.6852% | ||
| 05/11/24 | Free | Founder | 1,20,00,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.00% | -13.64% | -69.84% | -64.81% | 34.88L | |
| +2.83% | +4.40% | +60.84% | +123.50% | 1,16500Cr | |
| +3.81% | +5.66% | +38.70% | +74.91% | 64TCr | |
| +0.14% | +0.63% | +24.71% | +95.03% | 50TCr | |
| -0.45% | +3.06% | +43.89% | +64.51% | 38TCr | |
| -1.76% | +1.41% | +68.06% | +43.41% | 36TCr | |
| -0.50% | +2.95% | +22.83% | +51.93% | 30TCr | |
| -1.73% | +2.64% | +2.22% | +26.48% | 27TCr | |
| +2.04% | +3.05% | +51.12% | +60.42% | 24TCr | |
| +2.36% | -0.11% | +29.42% | +102.04% | 19TCr | |
| Average | -0.79% | +0.99% | +27.19% | +57.74% | 40.55TCr | |
| Weighted average by Cap. | -0.31% | +3.17% | +43.13% | +83.13% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -36.41L -48.67L -43.45L -40.08L -68.31L -46Cr -69.36L -4.83Cr -1.9Cr -24Cr -1.83Cr -1.79Cr -77Cr | -7L -9L -8L -7L -12.24L -8.26Cr -12.43L -86.53L -34.09L -4.33Cr -32.74L -32.04L -14Cr |
| Net Debt | -20.21T -27.01T -24.11T -22.24T -37.91T -25.59L -38.5T -3L -1L -13.41L -1L -99.23T -42.47L | -97.55T -1L -1L -1L -2L -1.24Cr -2L -12.93L -5L -64.71L -5L -5L -2.05Cr |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | GBX 0.0950 | -5.00% | 49,23,641 |
| 22/26/22 | GBX 0.1000 | -9.09% | 1,39,02,970 |
| 21/26/21 | GBX 0.1100 | +10.00% | 1,21,36,802 |
| 20/26/20 | GBX 0.1000 | -11.11% | 3,99,67,311 |
| 19/26/19 | GBX 0.1125 | +2.27% | 4,24,02,258 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
